FOLH1 and posterior cortical atrophy: We subsequently demonstrated that the constructed anti-PSMA Ab significantly enhanced specific antitumor effects against CRPC in adoptive human PB-NK cell therapy in vitro, in PDO, and in xenograft mouse models of PCa in vivo.